ORTX

1:21 $2.68

ORTX 1

Therapeutics

Orchard Therapeutics Plc is a

biopharmaceutical company, which engages in

discovering, acquiring, developing and

commercializing gene therapies for patients

with rare disorders. The company focuses on

its autologous ex vivo gene therapy approach

on three therapeutic rare disease franchise

areas: primary immune deficiencies,

neurometabolic disorders, and

hemoglobinopathies. Its portfolio includes

Strimvelis, a commercial-stage gamma

retroviral-based product for the treatment of

Adenosine deaminase deficiency (ADA-SCID).

The company was founded by Nicolas Koebel

and Andrea Spezzi in August 2018 and is

headquartered in London, the United Kingdom.

The listed name for ORTX is Orchard

Therapeutics pc American Depositary Shares.

Show Less

CEO Bobby Gaspar

Today's Volume Trade

710,388 Qu